SOLEUS CAPITAL MANAGEMENT L P
Q2 2024 Form 13-F
GREENWICH, CONNECTICUT
CIK 0001802630
· CRD 294459
· SEC-registered investment adviser
$1.1B Reported Value Total
SOLEUS CAPITAL MANAGEMENT, L.P. reports 8 total accounts under management (AUM). There are 8 discretionary accounts valued at $1,979,290,655, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
14 funds
· $3.8B gross asset value
Hedge Fund: $3.0B · Private Equity Fund: $765.8M
Source: Form ADV filed 2026-04-27
Reported value
$1.1B
Quarter over quarter
-8.9%
Holdings
92
Top-10 concentration
36.5%
Key People
Form ADV owners & control persons
Guy Bezalel Levy
SOLE OWNER
Charles Arthur Davis
MEMBER
Stephen Nmn Friedman
MEMBER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 14, 2024 |
| Form | 13F-HR |
| Reported value | $1.1B |
| Positions | 92 |
| Change in reported value | -15.8% |
| New positions | 26 |
| Exited positions | 24 |
| Position turnover | 43.1% |
| Top-10 concentration | 36.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 11, 2026
|
97 | $2.9B |
|
Q1 2026 13F
Filed May 14, 2026
|
93 | $2.5B |
|
Q4 2025 13F
Filed Feb 12, 2026
|
94 | $2.7B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
87 | $2.0B |
|
Q2 2025 13F
Filed Aug 15, 2025
|
94 | $1.5B |
|
Q1 2025 13F
Filed May 15, 2025
|
74 | $1.4B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
80 | $1.6B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
86 | $1.3B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
92 | $1.1B |
|
Q1 2024 13F
Filed May 15, 2024
|
90 | $1.3B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
73 | $901.2M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
90 | $1.1B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
101 | $899.5M |
|
Q1 2023 13F
Filed May 15, 2023
|
76 | $965.7M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
72 | $697.1M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
75 | $736.0M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
70 | $641.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
63 | $775.1M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
65 | $998.8M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
70 | $641.7M |
7 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | TGTX TG THERAPEUTICS INC | $64.9M | 5.72% |
| 2 | IOVA IOVANCE BIOTHERAPEUTICS INC | $60.5M | 5.34% |
| 3 | UTHR UNITED THERAPEUTICS CORP DEL | $45.1M | 3.97% |
| 4 | NRIX NURIX THERAPEUTICS INC | $42.9M | 3.78% |
| 5 | EDAP EDAP TMS S A | $39.7M | 3.5% |
| 6 | TERN TERNS PHARMACEUTICALS INC | $33.7M | 2.97% |
| 7 | RVMD REVOLUTION MEDICINES INC | $33.2M | 2.93% |
| 8 | SRDX SURMODICS INC | $32.9M | 2.9% |
| 9 | ORGO ORGANOGENESIS HLDGS INC | $32.3M | 2.84% |
| 10 | JSPR JASPER THERAPEUTICS INC | $29.0M | 2.55% |
| 11 | IDYA IDEAYA BIOSCIENCES INC | $24.4M | 2.15% |
| 12 | AXGN AXOGEN INC | $23.9M | 2.11% |
| 13 | KRYS KRYSTAL BIOTECH INC | $23.1M | 2.04% |
| 14 | MRUS MERUS N V | $22.3M | 1.96% |
| 15 | PEN PENUMBRA INC | $22.2M | 1.96% |
| 16 | EPIX ESSA PHARMA INC | $22.1M | 1.95% |
| 17 | PRAX PRAXIS PRECISION MEDICINES I | $22.0M | 1.94% |
| 18 | CELC CELCUITY INC | $19.8M | 1.75% |
| 19 | NARI INARI MED INC | $19.7M | 1.73% |
| 20 | ONC BEIGENE LTD | $19.6M | 1.73% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.